Technical Analysis for NVCR - NovoCure Limited

Grade Last Price % Change Price Change
grade C 47.04 -5.92% -2.96
NVCR closed down 5.92 percent on Friday, March 22, 2019, on 68 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical NVCR trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 MACD Bearish Centerline Cross Bearish 0.00%
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Wide Range Bar Range Expansion 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 21 50 DMA Support Bullish -5.92%
Mar 21 New Uptrend Bullish -5.92%
Mar 20 New Downtrend Bearish -5.66%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.66%

Older signals for NVCR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Medicine Cancer Clinical Medicine Oncology Non Small Cell Lung Cancer Tumor Ovarian Cancer Pancreatic Cancer Glioblastoma Brain Tumor European Union Aging Associated Diseases Solid Tumor Cancers Book:Cancer Mesothelioma
Is NVCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.67
52 Week Low 19.55
Average Volume 787,488
200-Day Moving Average 40.3633
50-Day Moving Average 49.762
20-Day Moving Average 51.1795
10-Day Moving Average 50.389
Average True Range 1.9672
ADX 25.34
+DI 21.9516
-DI 30.626
Chandelier Exit (Long, 3 ATRs ) 50.7684
Chandelier Exit (Short, 3 ATRs ) 52.5654
Upper Bollinger Band 55.7825
Lower Bollinger Band 46.5765
Percent B (%b) 0.05
BandWidth 17.987671
MACD Line -0.0891
MACD Signal Line 0.46
MACD Histogram -0.5491
Fundamentals Value
Market Cap 4.18 Billion
Num Shares 88.9 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -43.16
Price-to-Sales 13.08
Price-to-Book 13.88
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.43
Resistance 3 (R3) 54.04 52.53 52.36
Resistance 2 (R2) 52.53 50.90 52.22 52.01
Resistance 1 (R1) 49.78 49.89 49.02 49.17 51.65
Pivot Point 48.27 48.27 47.89 47.96 48.27
Support 1 (S1) 45.52 46.64 44.77 44.91 42.43
Support 2 (S2) 44.01 45.63 43.70 42.07
Support 3 (S3) 41.26 44.01 41.72
Support 4 (S4) 40.65